DCM
ALDR

Dupont Capital Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Dupont Capital Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-16,914
Closed -$352K – 1026
2017
Q1 		$352K Sell
16,914
-5,568
-25% -$123K 0.01% 762
2016
Q4 		$468K Buy
+22,482
New +$585K 0.01% 705

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Dupont Capital Management's ALDR Position: Q2 2017 in Review

Dupont Capital Management sold out of Alder Biopharmaceuticals (ALDR) in Q2 2017, closing a stake of 16,914 shares — an estimated $352K sold.

Dupont Capital Management first reported a position in ALDR in Q4 2016 and held it in 2 quarters. The position peaked at $468K in Q4 2016. 128 funds tracked by Wall St. Rank hold ALDR as of Q2 2017.

  • Dupont Capital Management reported no remaining Alder Biopharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Dupont Capital Management sold 16,914 Alder Biopharmaceuticals shares in Q2 2017, an estimated $352K.
  • Dupont Capital Management first reported a position in Alder Biopharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Dupont Capital Management's Alder Biopharmaceuticals position peaked at $468K in Q4 2016.
  • 128 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q2 2017.

Based on Dupont Capital Management's 13F filing for Q2 2017, filed 3 Aug 2017.